Specialty Tiers Ensure Part D Plans Cover High-Cost Biologics, Blum Says
Executive Summary
CMS Medicare director Jonathan Blum acknowledges there is a “robust debate” within CMS regarding specialty tiers in Part D but says he believes permitting plans to charge beneficiaries higher cost-sharing for expensive biologics preserves access to such drugs.